Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 16/20 | 0.34 |
| ▸ | CA1 | P00915 | 15/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 6/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934352 | 0.83 | ALDH1A1 (0.46) | CA2CA1CA12CA9KDM4E | |
| SCHEMBL935363 | 0.82 | ALDH1A1 (0.45) | CA2CA1CA12CA9KDM4E | |
| SCHEMBL11843588 | 0.80 | CA1 (0.47) | CA2CA1CA12CA9KDM4E | |
| SCHEMBL545256 | 0.80 | HTT (0.48) | SRCKDM4EALDH1A1HPGDHTT | |
| SCHEMBL23629772 | 0.78 | HTT (0.47) | SRCKDM4EALDH1A1HPGDHTT | |
| SCHEMBL935095 | 0.78 | HTT (0.47) | SRCKDM4EALDH1A1HPGDHTT | |
| SCHEMBL935126 | 0.78 | HTT (0.47) | SRCKDM4EALDH1A1HPGDHTT | |
| Hydrochloric Acid SCHEMBL934885 | 0.78 | HTT (0.47) | SRCKDM4EALDH1A1HPGDHTT | |
| SCHEMBL5797761 | 0.78 | ALDH1A1 (0.49) | CA2CA1CA12CA9KDM4E | |
| SCHEMBL9549613 | 0.77 | ALDH1A1 (0.47) | CA2CA1CA12CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | CA5B, CA3, CA1 | SRC 2261/4885CA2 12/4885CA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.